JP2022524018A5 - - Google Patents
Info
- Publication number
- JP2022524018A5 JP2022524018A5 JP2021552750A JP2021552750A JP2022524018A5 JP 2022524018 A5 JP2022524018 A5 JP 2022524018A5 JP 2021552750 A JP2021552750 A JP 2021552750A JP 2021552750 A JP2021552750 A JP 2021552750A JP 2022524018 A5 JP2022524018 A5 JP 2022524018A5
- Authority
- JP
- Japan
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025176328A JP2026016505A (ja) | 2019-03-06 | 2025-10-20 | Ｉｌ－１０バリアント分子ならびに炎症性疾患および腫瘍を処置する方法 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962814669P | 2019-03-06 | 2019-03-06 | |
| US62/814,669 | 2019-03-06 | ||
| US201962899504P | 2019-09-12 | 2019-09-12 | |
| US62/899,504 | 2019-09-12 | ||
| US202062962332P | 2020-01-17 | 2020-01-17 | |
| US62/962,332 | 2020-01-17 | ||
| PCT/US2020/021498 WO2020181235A1 (en) | 2019-03-06 | 2020-03-06 | Il-10 variant molecules and methods of treating inflammatory disease and oncology |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025176328A Division JP2026016505A (ja) | 2019-03-06 | 2025-10-20 | Ｉｌ－１０バリアント分子ならびに炎症性疾患および腫瘍を処置する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022524018A JP2022524018A (ja) | 2022-04-27 |
| JP2022524018A5 true JP2022524018A5 (https=) | 2023-04-26 |
| JPWO2020181235A5 JPWO2020181235A5 (https=) | 2023-04-26 |
Family
ID=72334859
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021552750A Withdrawn JP2022524018A (ja) | 2019-03-06 | 2020-03-06 | Ｉｌ－１０バリアント分子ならびに炎症性疾患および腫瘍を処置する方法 |
| JP2025176328A Pending JP2026016505A (ja) | 2019-03-06 | 2025-10-20 | Ｉｌ－１０バリアント分子ならびに炎症性疾患および腫瘍を処置する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025176328A Pending JP2026016505A (ja) | 2019-03-06 | 2025-10-20 | Ｉｌ－１０バリアント分子ならびに炎症性疾患および腫瘍を処置する方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (8) | US10858412B2 (https=) |
| EP (1) | EP3934681A4 (https=) |
| JP (2) | JP2022524018A (https=) |
| KR (1) | KR20210139312A (https=) |
| CN (2) | CN114072164A (https=) |
| CA (1) | CA3132385A1 (https=) |
| WO (1) | WO2020181235A1 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10017739B2 (en) * | 2012-09-06 | 2018-07-10 | Duke University | Methods of expanding and assessing B cells and using expanded B cells to treat disease |
| JP7641912B2 (ja) | 2019-04-19 | 2025-03-07 | シナーキン・ファーマ・ベスローテン・フエンノートシャップ | Ｉｌ１３を含む融合タンパク質 |
| WO2021231773A1 (en) | 2020-05-13 | 2021-11-18 | Good Therapeutics, Inc. | Compositions of protein complexes and methods of use thereof |
| CA3186753A1 (en) | 2020-07-20 | 2022-01-27 | John Mumm | Dual cytokine fusion proteins comprising il-10 |
| CN112898436A (zh) * | 2020-10-23 | 2021-06-04 | 广州医科大学附属肿瘤医院 | 一种具有靶向功能的鼠pd1和鼠il-15基因融合蛋白的表达及其应用 |
| KR102792982B1 (ko) * | 2021-05-28 | 2025-04-14 | 한양대학교 산학협력단 | 세포투과성 펩티드 및 이의 용도 |
| WO2023078245A1 (zh) * | 2021-11-02 | 2023-05-11 | 广东菲鹏制药股份有限公司 | Il10单体融合蛋白及其应用 |
| JP2024546938A (ja) * | 2021-12-13 | 2024-12-26 | デカ バイオサイエンシーズ， インコーポレイテッド | マルチサブユニットサイトカインを含む二重サイトカイン融合タンパク質 |
| JP2024546999A (ja) * | 2021-12-16 | 2024-12-26 | デカ バイオサイエンシーズ， インコーポレイテッド | Ｉｌ－１０を含む二重サイトカイン融合物およびがんを処置するための養子細胞療法または二重特異性ｔ細胞エンゲージャー |
| CN118900697A (zh) | 2022-02-22 | 2024-11-05 | 德卡生物科学公司 | 使用白细胞介素减轻双特异性t细胞接合器或嵌合抗原受体t细胞介导的细胞因子释放综合征的方法 |
| CN114632156B (zh) * | 2022-05-17 | 2022-08-16 | 中国人民解放军军事科学院军事医学研究院 | Tim-3在预防、治疗或减轻疼痛中的应用 |
| WO2024097875A1 (en) * | 2022-11-02 | 2024-05-10 | Shattuck Labs, Inc. | Fusion proteins for the treatment of nonalcoholic steatohepatitis |
| WO2024123812A1 (en) | 2022-12-05 | 2024-06-13 | Shattuck Labs, Inc. | Fusion proteins for the treatment of cardiometabolic diseases |
| WO2024249568A1 (en) | 2023-05-30 | 2024-12-05 | Paragon Therapeutics, Inc. | Alpha4beta7 integrin antibody compositions and methods of use |
| CN121889424A (zh) | 2023-08-14 | 2026-04-17 | 派拉冈医疗公司 | α4β7整联蛋白结合蛋白及使用方法 |
| KR20250078792A (ko) * | 2023-11-24 | 2025-06-04 | 주식회사 메드팩토 | 피브로넥틴 엑스트라도메인 B (Extradomain B of Fibronectin, EDB-FN) 및 전환성장인자 베타(transforming growth factor β, TGFβ)에 특이적으로 결합하는 융합 단백질 및 이의 용도 |
| CN121108363A (zh) * | 2024-06-12 | 2025-12-12 | 广东菲鹏制药股份有限公司 | 一种融合蛋白及其用途 |
| CN119613546B (zh) * | 2025-02-10 | 2025-05-13 | 细胞生态海河实验室 | Il-10抗体及其应用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA200802289A1 (ru) * | 2006-05-08 | 2009-04-28 | Филоджен Спа | Направляемые к мишени антителами цитокины для терапии |
| ES2536772T3 (es) * | 2007-09-21 | 2015-05-28 | The Regents Of The University Of California | El interferón dirigido demuestra potentes actividades apoptóticas y antitumorales |
| WO2009056268A1 (en) * | 2007-10-30 | 2009-05-07 | Philogen S.P.A. | An antigen associated with rheumatoid arthritis |
| NZ592420A (en) * | 2008-10-02 | 2012-12-21 | Emergent Product Dev Seattle | Cd86 antagonist multi-target binding proteins |
| WO2012045334A1 (en) * | 2010-10-05 | 2012-04-12 | Synthon Bv | Biologically active il-10 fusion proteins |
| EA201892619A1 (ru) * | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2 |
| CA2876285A1 (en) | 2012-08-08 | 2014-02-13 | Roche Glycart Ag | Interleukin-10 fusion proteins and uses thereof |
| RU2612878C2 (ru) * | 2012-10-03 | 2017-03-13 | Филоджен С.П.А. | Антигены, ассоциированные с воспалительным заболеванием кишечника |
| KR20160043927A (ko) | 2013-03-14 | 2016-04-22 | 파카쉬 길 | 세포 표면 grp78에 결합하는 항체를 사용하는 암 치료 |
| WO2015117930A1 (en) * | 2014-02-06 | 2015-08-13 | F. Hoffmann-La Roche Ag | Interleukine 10 immunoconjugates |
| CN104403004B (zh) * | 2014-11-24 | 2017-10-13 | 苏州丁孚靶点生物技术有限公司 | 抗体‑干扰素异二聚体的制备和用途 |
| AU2015364396B2 (en) * | 2014-12-19 | 2018-08-09 | Alkermes, Inc. | Single chain Fc fusion proteins |
| WO2017091611A1 (en) * | 2015-11-23 | 2017-06-01 | Immungene, Inc | Enhanced cancer immunotherapy using antibody-interferon fusion molecules |
| UY37003A (es) * | 2015-12-04 | 2017-06-30 | Novartis Ag | Composiciones de anticuerpo injertado con citoquina y métodos para su uso en inmunorregulacion |
-
2020
- 2020-03-06 JP JP2021552750A patent/JP2022524018A/ja not_active Withdrawn
- 2020-03-06 CA CA3132385A patent/CA3132385A1/en active Pending
- 2020-03-06 CN CN202080033670.7A patent/CN114072164A/zh active Pending
- 2020-03-06 EP EP20765677.8A patent/EP3934681A4/en active Pending
- 2020-03-06 CN CN202511790818.2A patent/CN121652287A/zh active Pending
- 2020-03-06 KR KR1020217032047A patent/KR20210139312A/ko active Pending
- 2020-03-06 US US16/811,718 patent/US10858412B2/en active Active
- 2020-03-06 WO PCT/US2020/021498 patent/WO2020181235A1/en not_active Ceased
- 2020-08-24 US US17/001,264 patent/US10975133B2/en active Active
- 2020-08-25 US US17/002,531 patent/US10981965B2/en active Active
- 2020-08-25 US US17/002,388 patent/US10975134B2/en active Active
- 2020-08-25 US US17/002,537 patent/US20210040168A1/en not_active Abandoned
- 2020-09-04 US US17/012,841 patent/US10981966B2/en active Active
-
2021
- 2021-05-17 US US17/322,394 patent/US20220106373A1/en not_active Abandoned
-
2024
- 2024-05-07 US US18/657,437 patent/US20240294591A1/en active Pending
-
2025
- 2025-10-20 JP JP2025176328A patent/JP2026016505A/ja active Pending